Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.48 |
| ▸ | ITGAV | P06756 | 14/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14195949 | 1.00 | ITGB3 (0.48) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL14195945 | 1.00 | ITGB3 (0.48) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL14195947 | 0.90 | ITGB3 (0.42) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL8487183 | 0.90 | ITGB3 (0.42) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL14195948 | 0.90 | ITGB3 (0.42) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL14224073 | 0.90 | ITGB3 (0.43) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL13344630 | 0.76 | ITGB3 (0.54) | ITGB3ITGAVITGA2BDPP4GRIN2B | |
| SCHEMBL4716833 | 0.74 | ITGB3 (0.56) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL8501348 | 0.74 | ITGB3 (0.48) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL8486338 | 0.74 | NPC1 (0.36) | GRIN2BNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351711-B2 | Tricyclic indanyls as integrin inhibitors | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2008-04-01 | — | — | US | disclosed |
| EP-1506779-B1 | (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina | JANSSEN PHARMACEUTICA NV (BE) | 2006-07-12 | — | — | EP | disclosed |
| EP-1506779-B1 | (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina | JANSSEN PHARMACEUTICA NV (BE) | 2006-07-12 | — | — | EP | disclosed |
| EP-1506779-A1 | (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| EP-1506779-A1 | (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| US-20050026917-A1 | Tricyclic indanyls as integrin inhibitors | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026917-A1 | Tricyclic indanyls as integrin inhibitors | ITGB1, ILK, ITGB2 | ITGB3 5/4885ITGAV 6/4885ITGA2B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.